Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1(ERCC1)in Treatment Decision
The study will specifically be looking at ERCC1 expression in pancreas cancer with regards
to its prognostic and predictive value as a biomarker for patients receiving Gem / Cis as
adjuvant therapy after resection.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival and overall survival as measured by CT scan every 3 months and clinical follow-up
every 3 months
No
Shishir Maithel, MD
Principal Investigator
Emory University Winship Cancer Institute
United States: Institutional Review Board
WCI1738-09
NCT01188109
July 2010
August 2014
Name | Location |
---|---|
Emory University Winship Cancer Institute | Atlanta, Georgia 30322 |